{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:59:54Z","timestamp":1794373194274,"version":"4.9.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["20209KY3Y7"],"award-info":[{"award-number":["20209KY3Y7"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.tranon.2024.102228","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T12:58:56Z","timestamp":1734785936000},"page":"102228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Martina","family":"Ruglioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crucitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7060-7088","authenticated-orcid":false,"given":"Giovanna Irene","family":"Luculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Sadeghi Gol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Chella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tranon.2024.102228_bib0001","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.tranon.2024.102228_bib0002","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41416-021-01519-2","article-title":"Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities","volume":"125","author":"Rosell","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2024.102228_bib0003","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00204-015-1524-7","article-title":"Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity","volume":"89","author":"Suda","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"4","key":"10.1016\/j.tranon.2024.102228_bib0004","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2024.102228_bib0005","first-page":"3887","article-title":"Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer","volume":"18","author":"Hong","year":"2019","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.tranon.2024.102228_bib0006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.18632\/oncotarget.186","article-title":"EGFR-mutated lung cancer: a paradigm of molecular oncology","volume":"1","author":"Zhang","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2024.102228_bib0007","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.2147\/DDDT.S119162","article-title":"Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.tranon.2024.102228_bib0008","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples","volume":"39","author":"Russano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2024.102228_bib0011","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","article-title":"The emerging role of cell-free DNA as a molecular marker for cancer management","volume":"17","author":"Bronkhorst","year":"2019","journal-title":"Biomol. Detect. Quantif."},{"key":"10.1016\/j.tranon.2024.102228_bib0012","doi-asserted-by":"crossref","first-page":"107458","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"24","key":"10.1016\/j.tranon.2024.102228_bib0013","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.3390\/cancers14246025","article-title":"Circulating tumor DNA-A novel biomarker of tumor progression and its favorable detection techniques","volume":"14","author":"Wen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2024.102228_bib0014","doi-asserted-by":"crossref","first-page":"943253","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front. Oncol."},{"issue":"155","key":"10.1016\/j.tranon.2024.102228_bib0015","doi-asserted-by":"crossref","first-page":"190052","DOI":"10.1183\/16000617.0052-2019","article-title":"Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages","volume":"29","author":"Guibert","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"21","key":"10.1016\/j.tranon.2024.102228_bib0016","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3390\/cancers13215403","article-title":"Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: a pilot study and a review of the literature","volume":"13","author":"Verz\u00e8","year":"2021","journal-title":"Cancers)"},{"key":"10.1016\/j.tranon.2024.102228_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"224","key":"10.1016\/j.tranon.2024.102228_bib0018","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0019","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1038\/s41598-018-30780-4","article-title":"The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis","volume":"8","author":"Passiglia","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect. Quantif."},{"issue":"6","key":"10.1016\/j.tranon.2024.102228_bib0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2024.102228_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2024.102228_bib0023","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.3928","article-title":"New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.tranon.2024.102228_bib54","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.tranon.2024.102228_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00408","article-title":"Does testing error underlie liquid biopsy discordance?","volume":"3","author":"Paweletz","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2024.102228_bib0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10147-013-0602-1","article-title":"Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer","volume":"19","author":"Keam","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0026","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/s12885-021-08713-8","article-title":"Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data","volume":"21","author":"Guti\u00e9rrez","year":"2021","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.tranon.2024.102228_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.11.002","article-title":"A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: data from LATAM population","volume":"174","author":"Heredia","year":"2022","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2024.102228_bib0028","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/1568009618666180308125110","article-title":"Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis","volume":"18","author":"Passiglia","year":"2018","journal-title":"Curr. Cancer Drug Targets."},{"issue":"11","key":"10.1016\/j.tranon.2024.102228_bib0029","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.tranon.2024.102228_bib0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2024.102228_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230622","article-title":"Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation","volume":"15","author":"Cho","year":"2020","journal-title":"PLoS. One"},{"issue":"20","key":"10.1016\/j.tranon.2024.102228_bib0032","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1002\/cncr.33118","article-title":"Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2024.102228_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2017.05.005","article-title":"Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients","volume":"109","author":"Zhu","year":"2017","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2024.102228_bib0034","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/0284186X.2019.1645354","article-title":"Lessons learned from routine, targeted assessment of liquid biopsies for","volume":"58","author":"Mondaca","year":"2019","journal-title":"Acta Oncol."},{"key":"10.1016\/j.tranon.2024.102228_bib0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2019.03.017","article-title":"From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC","volume":"131","author":"Bordi","year":"2019","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.tranon.2024.102228_bib0036","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2024.102228_bib0037","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-Specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2024.102228_bib0038","doi-asserted-by":"crossref","first-page":"20323","DOI":"10.1038\/s41598-023-45815-8","article-title":"Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC","volume":"13","author":"Ju","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.tranon.2024.102228_bib0039","first-page":"4208","article-title":"Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer","volume":"13","author":"Lin","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2024.102228_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMo Open."},{"issue":"2","key":"10.1016\/j.tranon.2024.102228_bib0041","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-World genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2024.102228_bib0042","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.tranon.2024.102228_bib0043","first-page":"9614","article-title":"Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients","volume":"10","author":"Li","year":"2017","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"4","key":"10.1016\/j.tranon.2024.102228_bib0044","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10142-023-01253-3","article-title":"CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma","volume":"23","author":"Li","year":"2023","journal-title":"Funct. Integr. Genomics"},{"issue":"9","key":"10.1016\/j.tranon.2024.102228_bib0045","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.tranon.2024.102228_bib0046","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas","volume":"18","author":"Schmidt","year":"1999","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.tranon.2024.102228_bib0047","first-page":"3937","article-title":"Functional evaluation of p53 and PTEN gene mutations in gliomas","volume":"6","author":"Kato","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2024.102228_bib0048","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1541-7786.MCR-09-0442","article-title":"Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation","volume":"8","author":"Jordan","year":"2010","journal-title":"Mol. Cancer Res."},{"issue":"22","key":"10.1016\/j.tranon.2024.102228_bib0049","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/86.22.1707","article-title":"High frequency of germline p53 mutations in childhood adrenocortical cancer","volume":"86","author":"Wagner","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2024.102228_bib0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12881-015-0169-y","article-title":"Germline TP53 mutational spectrum in French Canadians with breast cancer","volume":"16","author":"Arcand","year":"2015","journal-title":"BMC. Med. Genet."},{"issue":"6","key":"10.1016\/j.tranon.2024.102228_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijc.2910640606","article-title":"Incidence of germ-line p53 mutations in patients with gliomas","volume":"64","author":"Li","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2024.102228_bib0052","article-title":"Tumor fraction correlates with detection of actionable variants across >23,000 circulating tumor DNA samples. JCO Precis","volume":"6","author":"Husain","year":"2022","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.tranon.2024.102228_bib0053","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324003541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324003541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T23:02:03Z","timestamp":1737759723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324003541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":54,"alternative-id":["S1936523324003541"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102228","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102228"}}